KRON - upcoming catalystThis is not a financial advice!
Most info on the chart.
Needs to break 2.6 level for further upmove.
Trade carefully!
−1.95USD
−112.67 MUSD
6.29 MUSD
40.07 M
About Kronos Bio, Inc.
Sector
CEO
Norbert W. Bischofberger
Headquarters
San Mateo
Website
Employees (FY)
63
Founded
2017
ISIN
US50107A1043
FIGI
BBG00L072923
Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of KRON is 1.03 USD — it has decreased by 0.96% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Kronos Bio, Inc. stocks are traded under the ticker KRON.
Kronos Bio, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
KRON stock is 7.00% volatile and has beta coefficient of 2.04. Check out the list of the most volatile stocks — is Kronos Bio, Inc. there?
One year price forecast for Kronos Bio, Inc. has a max estimate of 6.00 USD and a min estimate of 2.50 USD.
KRON earnings for the last quarter are −0.54 USD whereas the estimation was −0.51 USD which accounts for −5.37% surprise. Estimated earnings for the next quarter are −0.53 USD. See more details about Kronos Bio, Inc. earnings.
Kronos Bio, Inc. revenue for the last quarter amounts to 917.00 K USD despite the estimated figure of 1.40 M USD. In the next quarter revenue is expected to reach 1.53 M USD.
Yes, you can track Kronos Bio, Inc. financials in yearly and quarterly reports right on TradingView.
KRON stock has fallen by 8.04% compared to the previous week, the month change is a 11.21% fall, over the last year Kronos Bio, Inc. has showed a 20.77% decrease.
KRON net income for the last quarter is −25.32 M USD, while the quarter before that showed −31.37 M USD of net income which accounts for 19.30% change. Track more Kronos Bio, Inc. financial stats to get the full picture.
Today Kronos Bio, Inc. has the market capitalization of 62.50 M, it has decreased by 5.51% over the last week.
No, KRON doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, KRON shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kronos Bio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 63.00 employees. See our rating of the largest employees — is Kronos Bio, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kronos Bio, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kronos Bio, Inc. stock shows the sell signal. See more of Kronos Bio, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Kronos Bio, Inc. future price: according to them, KRON price has a max estimate of 6.00 USD and a min estimate of 2.50 USD. Read a more detailed Kronos Bio, Inc. forecast: see what analysts think of Kronos Bio, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Kronos Bio, Inc. EBITDA is −115.61 M USD, and current EBITDA margin is −1.81 K%. See more stats in Kronos Bio, Inc. financial statements.